RxDoctor Payments Data

Swati Mungekar, MD

Internal Medicine · Los Gatos, CANPI 1629155064

Payments from drug & device makers

$1,848in general payments, 2019–2025

Across 42 payments — averaging $43.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$903
  • Amgen$373
  • Biosense Webster, Inc.$147
  • Bayer$118
  • Teva Pharmaceuticals USA, Inc.$105
  • Galderma Laboratories, L.p.$52
  • plus $149 from 4 others

What the payments were for

  • Food & beverage$1,78697%
  • Education$623%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,848 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$111,716
Medicare patients
185
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$36,786
OzempicSemaglutide18$34,656
TrulicityDulaglutide13$12,419
EntrestoSacubitril/Valsartan12$8,905
InvokanaCanagliflozin11$7,215
Levothyroxine Sodium146$2,233
Atorvastatin Calcium149$1,416
SynthroidLevothyroxine Sodium13$1,309
Rosuvastatin Calcium66$1,297
Lisinopril114$1,128
Ezetimibe32$1,104
Duloxetine Hcl25$1,055
Losartan Potassium88$1,035
Pantoprazole Sodium55$936
Simvastatin69$929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$12$12,41913 claims
AbbVieSynthroid$903$1,30913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Gatos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →